المؤلفون: Liu H; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Pan D; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Yao Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Wang H; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Li Y; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Qin X; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Qu P; Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Tang J; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: tm350347@163.com., Han Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: cnhzxyq@163.com.

المصدر: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112635. Date of Electronic Publication: 2024 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/mortality , Gemcitabine* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/therapeutic use , Deoxycytidine*/administration & dosage , Deoxycytidine*/adverse effects , Paclitaxel*/therapeutic use , Paclitaxel*/administration & dosage , Paclitaxel*/adverse effects , Albumins*/therapeutic use , Albumins*/administration & dosage , Albumins*/adverse effects , Indoles*/therapeutic use , Indoles*/administration & dosage , Indoles*/adverse effects , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Quinolines*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/administration & dosage ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome

المؤلفون: Zhang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Huang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Yang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou T; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Chen G; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhou H; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Ma Y; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Hong S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhao H; Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China., Zhang L; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. zhangli@sysucc.org.cn., Fang W; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. fangwf@sysucc.org.cn.

المصدر: Signal transduction and targeted therapy [Signal Transduct Target Ther] 2024 Sep 27; Vol. 9 (1), pp. 255. Date of Electronic Publication: 2024 Sep 27.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Etoposide*/administration & dosage , Etoposide*/adverse effects , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Aged ; Adult

المؤلفون: Sharman JP; Willamette Valley Cancer Center.; Sarah Cannon Research Institute.

المصدر: Blood [Blood] 2024 Sep 26; Vol. 144 (13), pp. 1351-1352.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/pathology , Pyrimidines*/administration & dosage , Pyrimidines*/therapeutic use , Piperidines*/administration & dosage , Piperidines*/therapeutic use , Pyrazoles*/administration & dosage , Pyrazoles*/therapeutic use , Adenine*/analogs & derivatives , Adenine*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/administration & dosage ; Nitriles/administration & dosage ; Nitriles/therapeutic use

المؤلفون: Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Cheah CY; Linear Clinical Research, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia., Coombs CC; Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA., Shah NN; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Wierda WG; MD Anderson Cancer Center, Houston, TX., Patel MR; Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL., Lamanna N; Columbia University Irving Medical Center, NewYork-Presbyterian, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Nair B; Loxo@Lilly, Indianapolis, IN., Wang C; Eli Lilly and Company, Indianapolis, IN., Zhao X; Loxo@Lilly, Indianapolis, IN., Liu D; Eli Lilly and Company, Indianapolis, IN., Radtke D; Eli Lilly and Company, Indianapolis, IN., Chapman S; Eli Lilly and Company, Indianapolis, IN., Marella N; Loxo@Lilly, Indianapolis, IN., McNeely SC; Loxo@Lilly, Indianapolis, IN., Brown JR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

المصدر: Blood [Blood] 2024 Sep 26; Vol. 144 (13), pp. 1374-1386.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Sulfonamides*/administration & dosage , Sulfonamides*/adverse effects , Sulfonamides*/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell*/mortality , Rituximab*/administration & dosage , Rituximab*/adverse effects , Bridged Bicyclo Compounds, Heterocyclic*/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic*/adverse effects , Bridged Bicyclo Compounds, Heterocyclic*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Aged ; Middle Aged ; Male ; Female ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use ; Aged, 80 and over ; Adult ; Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Pyrazoles/administration & dosage ; Pyrazoles/therapeutic use ; Pyrazoles/adverse effects

المؤلفون: Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Wang H; Department of Oncology, Tianjin Union Medical Centre, Nankai University, Tianjin, China., Feng J; Jiangsu Cancer Hospital, Nanjing, China., Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Tao R; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhang H; Department of Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Fogliatto L; Hematology and Hemotherapy Department, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Maluquer Artigal C; Medical Hematology Department, Institut Catala d'Oncologia Hospitalet; Instituto de Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Universitat de Barcelona, Barcelona, Spain., Özcan M; Ankara University School of Medicine, Ankara, Turkey., Yanez E; Sociedad de Investigaciones Medicas Ltda, Temuco, Chile., Kim WS; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea., Kirtbaya D; Oncology Dispensary No. 2, Sochi, Russia., Kriachok I; National Cancer Institute, Kiev, Ukraine., Maciel F; Division of Hematology, Transfusion Medicine and Cell Therapy, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Xue H; Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China., Bouabdallah K; Hematology and Cellular Therapy Department, University Hospital of Bordeaux, Bordeaux, France., Phelps C; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Chaturvedi S; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Weispfenning A; Bayer AG, Berlin, Germany., Morcos PN; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Odongo F; Bayer SA, São Paulo, Brazil., Buvaylo V; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Childs BH; Bayer HealthCare Pharmaceuticals Inc, Whippany, NJ., Dreyling M; Klinikum der Universität München LMU, Medizinische Klinik und Poliklinik III - Onkologie und Hämatologie, Munich, Germany., Matasar M; Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Ghione P; Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY.

المصدر: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4866-4876.

نوع المنشور: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Rituximab*/therapeutic use , Rituximab*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Pyrimidines*/therapeutic use , Pyrimidines*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/mortality ; Quinazolines/therapeutic use ; Quinazolines/administration & dosage ; Aged, 80 and over ; Treatment Outcome ; Double-Blind Method ; Recurrence

المؤلفون: Cannon TL; Inova Schar Cancer Institute, Fairfax, VA., Rothe M; American Society of Clinical Oncology, Alexandria, VA., Mangat PK; American Society of Clinical Oncology, Alexandria, VA., Garrett-Mayer E; American Society of Clinical Oncology, Alexandria, VA., Chiu VK; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA., Hwang J; Levine Cancer Institute, Atrium Health, Charlotte, NC., Vijayvergia N; Fox Chase Cancer Center, Philadelphia, PA., Alese OB; Winship Cancer Institute of Emory University, Atlanta, GA., Dib EG; Michigan Cancer Research Consortium, Ypsilanti, MI., Duvivier HL; City of Hope Atlanta, Newnan, GA., Klute KA; University of Nebraska Medical Center, Omaha, NE., Sahai V; University of Michigan Rogel Cancer Center, Ann Arbor, MI., Ahn ER; City of Hope Chicago, Zion, IL., Bedano P; Community Cancer Center South, Indianapolis, IN., Behl D; Sutter Sacramento Medical Center, Sacramento, CA., Sinclair S; Northern Light Cancer Center, Lafayette Family Cancer Institute, Brewer, ME., Thota R; Intermountain Healthcare, Murray, UT., Urba WJ; Providence Cancer Institute, Portland, OR., Yang ES; Department of Radiation Medicine, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY., Grantham GN; American Society of Clinical Oncology, Alexandria, VA., Hinshaw DC; American Society of Clinical Oncology, Alexandria, VA., Gregory A; American Society of Clinical Oncology, Alexandria, VA., Halabi S; Duke University Medical Center, Durham, NC., Schilsky RL; American Society of Clinical Oncology, Alexandria, VA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20; Vol. 42 (27), pp. 3228-3237. Date of Electronic Publication: 2024 May 15.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Receptor, ErbB-2*/metabolism , Biliary Tract Neoplasms*/drug therapy , Biliary Tract Neoplasms*/genetics , Biliary Tract Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Trastuzumab*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Receptor, ErbB-3*/metabolism , Receptor, ErbB-3*/genetics , Registries*, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Aged, 80 and over

المؤلفون: Mateos MV; Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC), Salamanca, Spain., Martínez-López J; Hematology Department, Hospital 12 de Octubre, Medicine Department, Medicine School of Complutense University, I+12. CNIO, Madrid, Spain., Rodriguez Otero P; Hematology Department, Cancer Center Clinica Universidad de Navarra (CCUN), Cima, CIBERONC, Pamplona, Spain., González-Calle V; Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Salamanca, Spain.; Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Gonzalez MS; Hematology Department, Hospital Clinico Universitario Santiago de Compostela, Santiago de Compostela, Spain., Oriol A; Clinical Hematology, Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Gutiérrez NC; Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.; Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Ríos-Tamayo R; Unidad de Gammapatías Monoclonales, Hospital Universitario Puerta de Hierro, Majadahonda, Spain., Rosiñol L; Hematology Department, Hospital Clinic, Barcelona, Spain., Alvarez Rivas MA; Servicio de Hematología y Hemoterapia, Hospital Universitario Reina Sofía, Córdoba, Spain., Bargay J; Hematology Department, Hospital Universitario Son Llatzer, IdISBa (Institut d'Investigació Sanitaria Illes Balears), Palma, Spain., Gonzalez-Rodriguez AP; Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Alegre A; Hematology Department, University Hospital La Princesa & University Hospital QuironSalud, Autonoma-University, Madrid, Spain., Escalante F; Servicio de Hematología, Unidad i+i, Complejo Asistencial Universitario de León, León, Spain., Iñigo Rodríguez MB; Hematology Department, Hospital Clínico San Carlos, Madrid, Spain., De La Rubia J; Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Universidad Católica de Valencia, Valencia, Spain.; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC CB16/12/00284, Instituto de Salud Carlos III, Madrid, Spain., Teruel AI; Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., de Arriba F; Servicio de Hematologia, Hospital Universitario Morales Meseguer, IMIB-Pascual Parrilla, Universidad de Murcia, Murcia, Spain., Palomera L; Hematology Department, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain., Hernández MT; Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Lopez Jiménez J; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain., Reinoso-Segura M; Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain., García Mateo A; Hematology Department, Complejo Asistencial de Segovia, Segovia, Spain., Ocio EM; Hematology Department, Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain., Paiva B; Hematology Department, Clinica Universidad de Navarra, Pamplona, Spain., Puig N; Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain., Cedena MT; Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain., Bladé J; Hematology Department, Hospital Clinic, IDIBARS, Barcelona, Spain., Lahuerta JJ; Instituto de Investigación, Hospital Universitario 12 de Octubre, Madrid, Spain., San-Miguel JF; Cancer Center Clinica Universidad de Navarra (CCUN), CIMA, IDISNA, CIBERONC, Pamplona, Spain.

مؤلفون مشاركون: Spanish Myeloma Group (GEM-Pethema)

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20; Vol. 42 (27), pp. 3247-3256. Date of Electronic Publication: 2024 Jul 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Lenalidomide*/administration & dosage , Lenalidomide*/therapeutic use , Lenalidomide*/adverse effects , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Oligopeptides*/therapeutic use , Oligopeptides*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Smoldering Multiple Myeloma*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Hematopoietic Stem Cell Transplantation/methods ; Transplantation, Autologous ; Melphalan/administration & dosage ; Melphalan/therapeutic use ; Consolidation Chemotherapy ; Maintenance Chemotherapy ; Multiple Myeloma/drug therapy ; Multiple Myeloma/therapy ; Disease Progression

المؤلفون: Ramaswamy A; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Bhargava P; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Srinivas S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kapoor A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mishra BK; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Gupta A; Department of Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India., Mandavkar S; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kannan S; Department of Statistics, Advanced Centre for Treatment, Research and Education in Cancer, Homi Bhabha National Institute (HBNI), Mumbai, India., Chaugule D; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Patil R; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Parulekar M; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Nashikkar C; Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ankathi SK; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Kaushal RK; Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Naughane D; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Daddi A; Department of Medicine, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Mer N; CRC, Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Shetty N; Department of Radiology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India., Ostwal V; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20; Vol. 42 (27), pp. 3218-3227. Date of Electronic Publication: 2024 Aug 05.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/administration & dosage , Bevacizumab*/adverse effects , Erlotinib Hydrochloride*/administration & dosage , Erlotinib Hydrochloride*/adverse effects , Erlotinib Hydrochloride*/therapeutic use , Gallbladder Neoplasms*/drug therapy , Gallbladder Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Cholangiocarcinoma*/drug therapy , Gemcitabine*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Progression-Free Survival ; Bile Duct Neoplasms/drug therapy ; Bile Duct Neoplasms/pathology

المؤلفون: Xiao X; Department of Hematology, The Second Affiliated Hospital, College of Medicine, ZhejiangUniversity, Hangzhou, China., Hu M; Department of Hematology, Affiliated Hospital of Shaoxing University(Shaoxing Municipal Hospital), Shaoxing, Zhejiang, People's Republic of China., Jiang H; Department of Hematology, The Second Affiliated Hospital, College of Medicine, ZhejiangUniversity, Hangzhou, China., Chen P; Department of Hematology, The Second Affiliated Hospital, College of Medicine, ZhejiangUniversity, Hangzhou, China., Lei H; Department of Hematology, Affiliated Hospital of Shaoxing University(Shaoxing Municipal Hospital), Shaoxing, Zhejiang, People's Republic of China. 450506193@qq.com.

المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Sep 19; Vol. 150 (9), pp. 425. Date of Electronic Publication: 2024 Sep 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Salvage Therapy*/methods , Lymphoma, T-Cell, Peripheral*/drug therapy , Lymphoma, T-Cell, Peripheral*/pathology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Gemcitabine* , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/therapeutic use , Deoxycytidine*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Aged ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Young Adult ; Organoplatinum Compounds

SCR Protocol: gemcitabine-oxaliplatin regimen

المؤلفون: Tu X; Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, No. 74, Linjiang Road, Yuzhong District, Chongqing Municipality, 400010, People's Republic of China., Zhang W; Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, No. 74, Linjiang Road, Yuzhong District, Chongqing Municipality, 400010, People's Republic of China., Li S; Department of Hepatobiliary Pancreatic Tumor Center, Chongqing University Cancer Hospital, Chongqing, No. 181, Hanyu Road, Shapingba District, Chongqing Municipality, 400010, People's Republic of China., He Q; Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, No. 74, Linjiang Road, Yuzhong District, Chongqing Municipality, 400010, People's Republic of China., Li Y; Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, No. 74, Linjiang Road, Yuzhong District, Chongqing Municipality, 400010, People's Republic of China. 300385@hospital.cqmu.edu.cn.

المصدر: European journal of medical research [Eur J Med Res] 2024 Sep 19; Vol. 29 (1), pp. 465. Date of Electronic Publication: 2024 Sep 19.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 9517857 Publication Model: Electronic Cited Medium: Internet ISSN: 2047-783X (Electronic) Linking ISSN: 09492321 NLM ISO Abbreviation: Eur J Med Res Subsets: MEDLINE

مواضيع طبية MeSH: Liver Neoplasms*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Portal Vein*/pathology , Infusions, Intra-Arterial* , Fluorouracil*/administration & dosage , Fluorouracil*/adverse effects , Oxaliplatin*/administration & dosage , Oxaliplatin*/therapeutic use , Oxaliplatin*/adverse effects , Organoplatinum Compounds*/administration & dosage , Organoplatinum Compounds*/therapeutic use , Venous Thrombosis*/drug therapy , Venous Thrombosis*/etiology , Leucovorin*/administration & dosage , Leucovorin*/therapeutic use , Leucovorin*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Hepatic Artery ; Thiophenes/administration & dosage ; Thiophenes/therapeutic use ; Quinazolines/administration & dosage ; Quinazolines/therapeutic use ; Quinazolines/adverse effects ; Retrospective Studies ; Chemoembolization, Therapeutic/methods

SCR Protocol: Folfox protocol